Sexually transmitted disease test kit Aptima®

gynecologyTrichomonas vaginalisclinical

Deliver accurate results with the Aptima® BV and Aptima® CV/TV assays. Vaginitis is a leading reason for OB/GYN visits.1-3 Most women have symptoms of vaginitis at some point during their lives. The prevalence in the United States is estimated to be 21.2 million (29.2%) among women ages 14-49.2 The vast majority (90%) of vaginitis is caused by bacterial vaginosis (BV), Candida vaginitis (CV) (commonly referred to as a yeast infection), or Trichomonas vaginalis (TV)—either individually or a combination of all three infections.1,4 Overlapping symptoms and co-infections make clinical diagnosis a challenge, and 30% of symptomatic women will go undiagnosed after clinical evaluation.5-8 Aptima Assays Deliver Highly Sensitive Quantitative Detection Across Multiple Targets With the prevalence of co-infections and similarity in symptoms, it is important to determine the underlying cause of vaginitis. Our assays: Deliver Objective Results CDC- and ACOG-recommended nucleic acid amplification tests (NAATs) deliver results that are more comprehensive and higher in sensitivity and specificity versus DNA probe and traditional clinical methods5, 9-11 Detect More Co‑infections Molecular NAATs can detect 3x more mixed infections than clinical diagnosis with wet mount, culture and Amsel’s criteria10 Help Improve Quality of Life Vaginitis can negatively impact a woman’s quality of life, particularly in those with recurrent symptoms. Proper diagnosis and treatment can reduce anxiety and discomfort.4 Detect with Certainty The FDA-cleared Aptima assays run on the Panther® system and provide easy-to-interpret qualitative results from highly sensitive quantitative detection.